Shuttle Pharmaceuticals Holdings Inc SHPH:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 12:55 PM EDT
0.3801quote price arrow down-0.0069 (-1.7829%)
Volume
17,569
52 week range
0.35 - 2.75
Loading...
  • Open0.39
  • Day High0.39
  • Day Low0.3705
  • Prev Close0.387
  • 52 Week High2.75
  • 52 Week High Date05/23/23
  • 52 Week Low0.35
  • 52 Week Low Date02/13/24

Key Stats

  • Market Cap6.384M
  • Shares Out16.79M
  • 10 Day Average Volume0.02M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-14.29

KEY STATS

  • Open0.39
  • Day High0.39
  • Day Low0.3705
  • Prev Close0.387
  • 52 Week High2.75
  • 52 Week High Date05/23/23
  • 52 Week Low0.35
  • 52 Week Low Date02/13/24
  • Market Cap6.384M
  • Shares Out16.79M
  • 10 Day Average Volume0.02M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-14.29

RATIOS/PROFITABILITY

  • EPS (TTM)-0.44
  • P/E (TTM)-0.86
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-5.886M
  • ROE (TTM)-112.37%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)18.03%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Shuttle Pharmaceuticals Holdings Inc

 

Profile

MORE
Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company. The Company is focused on improving the outcomes of cancer patients treated with radiation therapy (RT). It is developing a pipeline of products designed to address cancer therapies as well as to extend to the new applications of radiation therapy. Its product candidates include Ropidoxuridine (IPdR), Ropidoxuridine and Tipracil (IPdR/TPI), SP-1-161, SP-2-225, and...
Anatoly Dritschilo M.D.
Chairman of the Board, Chief Executive Officer
Peter Dritschilo
President, Chief Operating Officer
Michael Vander Hoek
Chief Financial Officer, Vice President - Operations and Regulatory
Address
401 Professional Drive, Suite 260
Gaithersburg, MD
20879
United States